The combination of xanthine oxidase inhibitor febuxostat (FBX) with acetaminophen (ACE) is widely used in the treatment of gout. A rapid, simple, selective, and precise densitometric method was developed and validated for the simultaneous estimation of FBX-ACE mixture in a synthetic binary mixture and in their pharmaceutical dosage forms. The method employed thin-layer chromatography (TLC) aluminum plates precoated with silica gel G 60 F 254 as the stationary phase using chloroform-methanolcyclohexane-acetic acid 96% (7:1:1:0.1, v/v) as the mobile phase. The optimized mobile phase selected for development gave compact bands (R f values were 0.65 and 0.46 for FBX and ACE, respectively). Spectrodensitometric scanning integration was performed using dual-wavelength detection at 320 and 250 nm for FBX and ACE, respectively. The linear regression data for the calibration plots showed excellent linear relationship (r = 0.9997 and 0.9992 for FBX and ACE, respectively). The method was validated for precision, accuracy, robustness, and recovery. The limits of detection and quantification were calculated. The statistical analysis proved that the method is reproducible and selective for the estimation of this binary mixture.
Introduction
Gout is an increasingly common rheumatic disease. Global studies have found an increase in the mean serum urate in both genders during the past four decades. Uric acid is the final product of the metabolism of endogenous and exogenous purine in humans [1] . An excess of uric acid, measured in the plasma as sodium urate, constitutes hyperuricemia. The presence of urate crystals in the synovial fluid leads to an inflammatory response in the affected joint, commonly at the base of the big toe (podagra). The ensuing exquisite pain, tenderness, erythema, and swelling constitute the main clinical manifestations of acute inflammatory gouty arthritis. Repeated acute attacks may be associated with a visible or palpable buildup of crystal deposits (tophi) at various sites including in and around the affected joint. Tophi release urate crystals into the synovial fluid after various stimuli and thus cause further acute attacks, leading to chronic tophaceous gout [2] . Treatment for hyperuricemia in gout can be achieved by using urate-lowering drugs. These drugs are classified into three main groups: xanthine oxidase inhibitors, uricosurics, and recombinant uricases [3, 4] . Xanthine oxidase inhibitors (XOIs) are the oldest agents but still the first line for the treatment of hyperuricemia in gout. This group includes allopurinol and febuxostat (FBX). Febuxostat (FBX), chemically known as 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid, is a novel non-purine selective inhibitor of xanthine oxidase used for the treatment of hyperuricemia in gout by non-competitively blocking the molybdenum pterin center which is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, FBX inhibits xanthine oxidase, therefore reducing the production of uric acid. FBX inhibits both oxidized as well as reduced form of xanthine oxidase because of which FBX cannot be easily displaced from the molybdenum pterin site [5] . A committee of the British National Institute for Health and Clinical Excellence concluded that FBX is more potent and efficient than fixed-dose (300 mg) allopurinol in lowering serum uric acid concentration and the committee recommended FBX for people who are intolerant of allopurinol. Unlike allopurinol, there have been no reported significant drug-drug interactions and no hypersensitivity syndrome was encountered with FBX [1, 2, 5] . Pain associated with the attack of acute inflammatory gouty arthritis is best treated as soon as possible with a non-steroidal anti-inflammatory drug (NSAID). Aspirin or other salicylates are not suitable since they may increase plasma-urate concentrations. Painkillers, such as acetaminophen or acetaminophen and codeine, are useful for pain relief [6] . The combination of FBX and acetaminophen (ACE) is intended for the treatment of gout. ACE is a para-aminophenol derivative that has analgesic and antipyretic properties and weak anti-inflammatory activity. It is used for mild to moderate pain and for fever. ACE is often the analgesic or antipyretic of choice, especially in the elderly and in patients in whom salicylates or other NSAIDs are contra-indicated [2] .
The chemical structures of FBX and ACE are given in Figure 1 . Many procedures have been described for the quantitative determination of FBX and ACE alone or in combination with other drugs in the literature. Among these methods are liquid chromatography (LC) [7] [8] [9] [10] [11] [12] [13] , gas chromatography (GC) [14] [15] [16] [17] , thin-layer chromatography (TLC) [18] [19] [20] [21] [22] [23] [24] , and spectrophotometric [25] [26] [27] [28] [29] [30] and fluorimetric methods [31] [32] [33] [34] .
In the present study, a rapid and simple thin-layer chromatographic method using densitometric analysis was developed and validated for the simultaneous determination of the investigated drugs, present in binary mixture (FBX-ACE) in synthetic mixture and in their pharmaceutical formulations. The proposed method provides an inexpensive tool for the determination of the studied drugs in quality-control laboratories. Simplicity and sensitivity of the proposed method are superior in comparison with other reported densitometric methods for single or binary preparations containing any of the investigated drugs. In the previously reported methods, procedures are more complicated (samples allowed to dry for at least 2 h, then internal standard was applied) [35] . Also, the use of expensive nonbonded reversed-phase thin-layer chromatography (RP-TLC) plates that are detected by desorption electrospray ionization (DESI) was combined with ion mobility mass spectrometry (IM-MS) [36] . On the other hand, the spots were located by iodine vapors followed by evaporation and cutting the spots then filtration [37] . The sensitivity of the proposed method is superior in comparison with other reported densitometric methods for single or binary preparations containing any of the investigated drugs. In our method, the limit of detection (LOD) and limit of quantification (LOQ) (0.038, 0.11 mg per band for FBX and 0.016, 0.0499 mg per band for ACE, respectively) which are indicative of sensitivity of the method are lower than those of other previously reported methods [18, 21, 24] . The use of the proposed method expands the applicability in either dosage forms or biological fluids.
Until now, to our knowledge, the tested binary mixture has not been separated and no attempts have yet been made to assay this drug combination by any analytical method including high-performance thin-layer chromatography (HPTLC). 
Materials and Reagents
TLC aluminum sheets precoated with silica gel G 60 F 254 plates (Fluka, 20 × 20 cm, 0.20 mm layer thickness) were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). FBX was kindly supplied by Eva Pharma Pharmaceutical Company (Obour, Egypt). ACE was kindly supplied by Global Napi Pharmaceutical Company (Giza, Egypt). All pharmaceuticals were checked for purity by TLC. Chloroform, methanol, and acetic acid solution 96% were supplied by El-Nasr Pharmaceutical Chemicals Co. (Cairo, Egypt). Cyclohexane for liquid chromatography LiChrosolv ® was supplied by Merck Millipore Co. (Billerica, MA, USA). All other chemicals and reagents used in this study were of analytical grade.
Pharmaceutical Formulations
Goutifade film-coated tablets labeled to contain 80 mg FBX per tablet manufactured by Global Napi Pharmaceutical Company (Giza, Egypt) and Paracetamol ® tablets labeled to contain 500 mg ACE per tablet manufactured by El-Nasr Pharmaceutical Chemicals Company (ADWIC; Cairo, Egypt).) were purchased from the Egyptian local market. They were used to analyze FBX and ACE in their laboratory-made pharmaceutical preparations.
Preparation of Standard Solution of the Synthetic Mixture
Standard stock solution of the synthetic mixture containing 2.0 and 1.0 mg mL −1 of FBX and ACE was prepared in 25-mL volumetric flask by dissolving 50.0 mg FBX and 25.0 mg ACE in methanol. Regarding the stability of the drugs solution, stock solution was stored at 4°C in amber glass vessels and was found to be stable for at least 10 days. The working solutions were prepared by dilution of the standard stock solution with methanol. Different volumes corresponding to concentrations in the range of 0.05-1.5 and 0.025-0.75 mg mL −1 for FBX and ACE, respectively, were diluted with methanol in 10-mL volumetric flasks.
Chromatographic Conditions

General Procedure
TLC was performed on 20 × 20 cm aluminum foilbacked plates precoated with 0.20 mm layers of silica gel G 60 F 254 . Before use, the plates were cut into 20 × 5 cm pieces. Chloroform-methanol-cyclohexane-acetic acid (96 %) (7:1:1: 0.1, v/v) was used as the mobile phase. The TLC plates were developed in a conventional TLC tank (27.0 cm [width] × 26.5 cm [height] × 7.0 cm [diameter]); the tank was partially lined with thick filter paper to promote chamber saturation. The mobile phase (50 mL) was poured into the tank which is covered with its lid and pre-saturated with mobile phase vapor at room temperature (25 ± 5°C) for at least 30 min before use.
Working standard solutions and/or sample solutions (2 mL) were applied to the plates, 1 cm from the lower edge, with a Linomat 5 automatic sample applicator. The plates were dried in air for 5 min, then transferred to the TLC tank and developed with the selected mobile phase until the ascended solvent front moved about three-fourths the length of the plate from the origin (approximately 5 min). After development, the plates were removed, dried in air for about 5 min, and scanned by a CAMAG dual-wavelength TLC Scanner III with winCATS version 4.0 software in the absorbance mode at 320 nm and 250 nm for FBX and ACE, respectively.
Construction of Calibration Curves
Working standard solutions (2 mL) containing different concentrations of the FBX-ACE present in the binary mixture were prepared (0.10-3.00 and 0.050-1.50 mg band −1 of FBX and ACE, respectively). The working synthetic mixture solutions of the binary mixture were spotted in triplicate on the TLC plates. The plates were then developed, and densitometric analysis was performed as described under general procedure.
The data of peak area versus drug concentration was treated by linear least square regression analysis.
Analysis of Laboratory-Prepared Pharmaceutical Preparations
Twenty tablets of Goutifade and Paracetamol ® each were separately weighed and ground. Accurately weighed amounts of the separate tablet powder equivalent to 100.0 mg of FBX and 50.0 mg of ACE were transferred to a 50-mL volumetric flask and suspended in 30 mL methanol. The contents of the flask were sonicated for 15 min, and the solution was then diluted to 50 mL with the same solvent, mixed well, and filtered through Whatman No. 1 filter paper; the first portion of the filtrate was rejected. Further dilution to obtain sample solution containing FBX to ACE (2:1) was spotted onto the plate followed by development and scanning as described under the general procedure. The analysis was repeated in triplicate.
Validation
The method was validated according to the International Conference on Harmonization (ICH) guidelines on the validation of analytical methods, including specificity, linearity, LOD, LOQ, precision, accuracy, recovery, and robustness [38] . All the results were expressed as percentages, with n representing the number of samples.
Linearity
Linearity was determined by plotting peak area versus drug concentration. Linearity of the peak area response was verified at six concentration levels by making three measurements for each concentration. The slopes, intercepts, and correlation coefficients obtained by the linear least squares regression treatment of the results were calculated.
Limits of Detection and Quantification
LOD and LOQ were calculated as 3.3 σ/S and 10 σ/S, respectively, where σ is the standard deviation of the y-intercept of the regression equation and S is the slope of the calibration curve.
Accuracy
The accuracy of the method was determined by investigating the recovery percentage of each of the studied drugs at three concentration levels covering the low, medium, and high ranges of the calibration plot by spotting on a TLC plate (n = 6 for each concentration level). The resulting bands were analyzed by use of the TLC method described above and calculated from the calibration curves carried out simultaneously on the same TLC plate. Accuracy was expressed as percentage recovery [(Observed concentration / Theoretical concentration) × 100].
Precision
Intra-day precision of the proposed method was tested by replicate analysis of three separate solutions of the working standard mixture of FBX-ACE at three different concentration levels: low, medium, and higher ranges of the calibration curve. This study was repeated for 3 days to determine the inter-day precision (n = 6). Precision was expressed in relative standard deviation (RSD).
Recovery
The recovery of the proposed method was determined using the standard addition technique, by adding a known amount of standard at three different levels to the pre-analyzed sample.
Robustness
The robustness of the proposed method was determined by studying the effect of minor changes on the peak area of the band including the composition of mobile phase, saturation time, and analytical wavelength on the method performance.
Specificity
According to the ICH guidelines, it is always possible to demonstrate that an analytical procedure is specific for a particular analyte (complete discrimination). In this case, a combination of two or more analytical procedures is recommended to achieve the necessary level of discrimination. The specificity of the method was ascertained by analyzing standard drug and sample. The bands of the investigated drugs in sample were confirmed by comparing the R f and spectra of the bands with those of the standard. The peak purity of the studied drugs was assessed by comparing the spectra at three different levels, i.e., peak start (S), peak apex (M), and peak end (E) positions of the band [39] .
Results and Discussion
In this study, the binary mixture of FBX with an analgesic drug (ACE) was determined by dual-wavelength TLC-densitometry.
Optimization of Chromatographic Conditions
Several trials were conducted to select the most suitable mobile phase for the studied binary mixture (Table 1) .
Chloroform-methanol-cyclohexane-acetic acid (96%) (7:1:1:0.1, v/v) was the optimum mobile phase giving compact bands for each drug, with suitable R f values, and it was chosen for spectrodensitometric analysis. The typical chromatogram for the tested drugs in the mixture is presented in Figure 2. 
Validation of the Developed Method
Linearity
Under the described experimental conditions, the standard calibration curves for the binary mixture FBX-ACE were constructed by plotting peak area against concentration.
The concentration ranges of the final solutions and the linear regression equation parameters for each drug are cited in Table 2 . The correlation coefficients were in the range 0.9992-0.9997, indicating good linearity.
Detection and Quantification Limits
The values obtained for the limit of detection (LOD) and limit of quantification (LOQ) were indicative of a high sensitivity of the proposed method. LOD and LOQ were 0.038 and 0.110 mg per band for FBX, while 0.016 and 0.0499 mg per band for ACE (Table 2) .
Precision and Accuracy
%RSD values for FBX-ACE mixture for intra-day and interday precision were in the range from 0.32 to 1.79, indicating good repeatability (Table 3) . Accuracy was determined by comparing the measured concentrations of the FBX-ACE mixture with the actual values as expressed in percentages in Table  4 . The recoveries of the developed method for the studied drugs were in the range from 98.83% to 101.16%, indicating acceptable accuracy. The obtained accuracy and precision were satisfactory for quality-control measurements.
Robustness
The robustness of an analytical procedure refers to its capability to remain unaffected by small and deliberate variations in the method parameters without changes in quantification. The most critical conditions were changed, the chromatographic behavior was observed and recorded, and % recovery was calculated. For determination of the robustness of the method, three factors were selected from the analytical procedure to be examined in the robustness testing:
(a) the mobile phase composition (the mobile phase for the studied binary mixture with the component solvents in different proportions were investigated three times at each concentration level);
(b) saturation time;
(c) analytical wavelength. Table 2 Optimum conditions and quantitative parameters of the proposed spectrodensitometric method for the determination of febuxostatacetaminophen (FBX-ACE) mixture. In Table 5 , it was found that none of these variables had a significant effect on the determination of the investigated drugs.
FBX-ACE
The low values of RSD along with the nearly unchanged R f values obtained after introducing small deliberate changes in the method parameters provide an indication of the reliability of the proposed method during normal usage, so the developed spectrodensitometric method is considered robust.
Specificity
Good correlation was obtained between standard and sample spectra of FBX-ACE mixture. The comparative spectra of each drug in standard and sample are given in Figure 3 . Also, the results of comparison between peaks start, maximum, and end indicate the closeness in these positions between dosage forms and standards. This confirms the peak purity and identity.
Application of the Developed Method to Pharmaceutical Preparations
Laboratory-prepared solutions of Goutifade and Paracetamol ® tablets (the commercial dosage form in the local market) were prepared and successfully analyzed by the proposed HPTLC method. Results were compared with those obtained by the reported methods [19] for FBX and [24] for ACE, as shown in Table 6 . It was observed that there was no significant difference between the results obtained by the developed method and the reported methods [19, 24] for the mixture components as indicated by t and F tests. Additionally, recovery experiments were carried out for the studied drugs in their respective pharmaceutical formulations by standard addition method. The results in Table 7 indicate that the developed method is convenient for the investigated drugs with good recoveries and there is no interference from either the co-administered drugs or the frequently Table 3 Intra-day and inter-day precision of the proposed spectrodensitometric method for febuxostat-acetaminophen (FBX-ACE) mixture.
Inter-day precision Intra-day precision Concentration [µg band Figure 4 .
Conclusion
The TLC-densitometric method developed by us is simple, sensitive, and specific. The statistical analysis proves that the method is reproducible and selective for the simultaneous estimation of a non-purine selective xanthine oxidase inhibitor (febuxostat) in combination with acetaminophen in synthetic mixture and in pharmaceutical dosage forms. To our knowledge, there is no reported method for the determination of febuxostat with acetaminophen in binary mixture. The proposed method is precise, accurate, and convenient. In addition, the suggested method offers high sensitivity compared to other Table 6 Assay of the laboratory-made pharmaceutical dosage form of the investigated febuxostat-acetaminophen (FBX-ACE) mixture by the developed method and reported methods.
FBX ACE
% Recovery ± SD reported TLC methods developed for the determination of the studied drugs in other mixtures. Thus, the use of the proposed method expands the applicability in either dosage forms or biological fluids. On the other hand, the applicability of the proposed methods to real life situations was assessed through the analysis of laboratory-prepared solutions and satisfactory results were obtained. Hence, the proposed method should be useful for routine quality-control purposes and it could be advantageous in content uniformity testing.
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